# Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

> **NCT05387837** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ashvattha Therapeutics, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema

## Interventions

- **DRUG:** D-4517.2

## Key facts

- **NCT ID:** NCT05387837
- **Lead sponsor:** Ashvattha Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-31
- **Primary completion:** 2025-05-09
- **Final completion:** 2025-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387837, "Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05387837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*